Adverum Biotechnologies, Inc.

LSE:0HA3 Stock Report

Market Cap: US$94.0m

Adverum Biotechnologies Management

Management criteria checks 3/4

Adverum Biotechnologies' CEO is Laurent Fischer, appointed in Jun 2020, has a tenure of 4.58 years. total yearly compensation is $1.55M, comprised of 43.4% salary and 56.6% bonuses, including company stock and options. directly owns 0.34% of the company’s shares, worth $318.27K. The average tenure of the management team and the board of directors is 3 years and 4.7 years respectively.

Key information

Laurent Fischer

Chief executive officer

US$1.5m

Total compensation

CEO salary percentage43.4%
CEO tenure4.6yrs
CEO ownership0.3%
Management average tenure3yrs
Board average tenure4.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Laurent Fischer's remuneration changed compared to Adverum Biotechnologies's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$94m

Jun 30 2024n/an/a

-US$100m

Mar 31 2024n/an/a

-US$113m

Dec 31 2023US$2mUS$672k

-US$117m

Sep 30 2023n/an/a

-US$126m

Jun 30 2023n/an/a

-US$133m

Mar 31 2023n/an/a

-US$146m

Dec 31 2022US$3mUS$646k

-US$155m

Sep 30 2022n/an/a

-US$156m

Jun 30 2022n/an/a

-US$154m

Mar 31 2022n/an/a

-US$155m

Dec 31 2021US$9mUS$621k

-US$146m

Sep 30 2021n/an/a

-US$149m

Jun 30 2021n/an/a

-US$138m

Mar 31 2021n/an/a

-US$123m

Dec 31 2020US$22mUS$327k

-US$118m

Compensation vs Market: Laurent's total compensation ($USD1.55M) is above average for companies of similar size in the UK market ($USD346.88K).

Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.

CEO

Laurent Fischer (60 yo)

4.6yrs

Tenure

US$1,546,477

Compensation

Dr. Laurent Fischer, M.D., serves as Chair of the Board of Teal Omics Inc. He has been the Independent Supervisory Director of Atai Life Science N.V. since May 2024. He is Advisor of FORM Life Ventures. He...

Leadership Team

NamePositionTenureCompensationOwnership
Laurent Fischer
President4.6yrsUS$1.55m0.34%
$ 318.3k
Linda Rubinstein
CFO, Principal Financial Officer & Principal Accounting Officer2.1yrsUS$2.30m0.048%
$ 45.2k
Kishor Soparkar
Chief Operating Officer3.6yrsUS$903.02k0.13%
$ 125.6k
Setareh Seyedkazemi
Chief Development Officer3yrsUS$799.36k0.026%
$ 24.3k
Rabia Ozden
Chief Medical Officerless than a yearUS$94.20k0%
$ 0
R. Ramelmeier
Chief Technology Officer1.4yrsno datano data
Romuald Corbau
Chief Scientific Officerless than a yearno datano data
John Rakow
Senior VP & General Counsel3.5yrsUS$1.33mno data
Dena House
Chief People Officer5.4yrsno datano data
Carla Fiankan
Senior Vice President of Regulatory Affairs3yrsno datano data
Michael Steel
Senior Vice President of Quality3.3yrsno datano data
Heikki Jouttijarvi
Senior VP of Manufacturing & Supply Chain Management and Head of Technical Operationsno datano datano data

3.0yrs

Average Tenure

56.5yo

Average Age

Experienced Management: 0HA3's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Laurent Fischer
President4.6yrsUS$1.55m0.34%
$ 318.3k
James Scopa
Independent Director5.7yrsUS$111.70k0.050%
$ 46.7k
Scott Whitcup
Independent Director4.8yrsUS$106.70k0%
$ 0
David Boyer
Scientific Advisory Board Memberno datano datano data
C. Machado
Independent Chairman7.8yrsUS$163.80k0.042%
$ 39.9k
Jeffrey Heier
Scientific Advisory Board Memberno datano datano data
Reed Tuckson
Independent Director3.9yrsUS$99.20k0%
$ 0
Dawn Svoronos
Independent Director4.1yrsUS$106.70k0.024%
$ 22.6k
Mark Lupher
Independent Director5.7yrsUS$99.20k0.062%
$ 58.8k
Charles Wykoff
Scientific Advisory Board Memberno datano datano data
Arshad Khanani
Scientific Advisory Board Memberno datano datano data
Szilard Kiss
Directorless than a yearno datano data

4.7yrs

Average Tenure

63yo

Average Age

Experienced Board: 0HA3's board of directors are considered experienced (4.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 21:32
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adverum Biotechnologies, Inc. is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alethia YoungCantor Fitzgerald & Co.
Gbolahan Amusa BenzChardan Capital Markets, LLC
Daniil GataulinChardan Capital Markets, LLC